Reprieve Cardiovascular emerged from stealth mode this week with sizable financial backing and some big name board members to advance development for its intelligent, automated diuretic and fluid management system for heart failure.

Researchers explored data from nearly 17,000 U.S. heart transplant candidates, developing an updated model that ranks patients based on their mortality risk. 

New Jersey-based Impulse Dynamics says it will use the new financing to fund clinical research and continue developing advanced heart failure devices. 

Scot Pollard has a long family history of heart disease, and he’s been on a watch list for several years now due to his size. He's been in and out of hospitals for more than three years due to an ongoing fight with cardiomyopathy. 

Francisco Arabia, MD, spoke with Cardiovascular Business about the present and future of total artificial heart technology.

Researchers are presently tracking the safety and effectiveness of the new device in patients with ADHF compared to diuretics alone. 

New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

The CDC defines severe obesity, or class III obesity, as any patient with a BMI of 40 or higher. TAVR among these patients is not associated with a lower survival rate, but it does lead to many more risks.